R lipoic acid ( DrugBank: Lipoic acid )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00676156 (ClinicalTrials.gov) | December 2005 | 7/5/2008 | A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis | A Pilot Trial to Study the Pharmacokinetics of Oral Lipoic Acid (LA) and Immunological Effects of LA in Multiple Sclerosis | Multiple Sclerosis | Drug: oral lipoic acid (LA);Drug: lipoic acid (LA) with fish oil and LA without fish oil;Drug: R lipoic acid | Oregon Health and Science University | National Center for Complementary and Integrative Health (NCCIH) | Completed | 18 Years | 80 Years | Both | 40 | Phase 1 | United States |